Aethlon Medical price target lowered to $7 from $10 at H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino lowered the firm’s price target on Aethlon Medical to $7 from $10 and keeps a Buy rating on the shares after the company announced the Human Research Ethics Committee of the Central Adelaide Local Health Network granted full ethics approval valid for three years for its plan to conduct a safety, feasibility, and dose-finding clinical trial with the company’s Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy with Keytruda or Opdivo. The firm cites share dilution from the recently completed financing for the target drop.